WM-8014: Selective KAT6A/B Inhibition for Precision Epigenetic Modulation

Executive Summary: WM-8014 is a reversible, highly selective inhibitor targeting KAT6A, KAT6B, KAT5, and KAT7 with IC₅₀ values of 8 nM, 28 nM, 224 nM, and 342 nM, respectively, through competitive binding at the acetyl-CoA site (APExBIO product page). It induces cell cycle arrest and senescence via the p16^INK4A–p19^ARF pathway without broad cytotoxicity, as shown by upregulation of Cdkn2a and downregulation of Cdc6 in MEFs (bioRxiv 2025). In vivo zebrafish models demonstrate concentration-dependent reduction in liver volume and S-phase entry, specifically in KRAS G12V-driven hepatocyte overproliferation (bioRxiv). WM-8014 is highly soluble in DMSO (≥76.1 mg/mL) but has limited aqueous solubility. Due to high plasma-protein binding, derivatization (e.g., WM-1119) is recommended for in vivo mammalian studies (APExBIO).

Biological Rationale

KAT6A (MOZ) and KAT6B (MORF/QKF) are members of the MYST family of histone lysine acetyltransferases. These enzymes catalyze acetylation of histone H3 on lysine 9 and lysine 14, modulating chromatin accessibility and transcriptional activation in cell cycle regulation and oncogenesis (bioRxiv). Dysregulation of KAT6A/B activity is linked to tumorigenesis and resistance to oncogene-induced senescence. Targeting these enzymes with selective small molecules such as WM-8014 enables researchers to dissect epigenetic dependencies and modulate senescence pathways with high specificity. This approach facilitates functional genomics screens, such as those enabled by RESTRICT-seq, identifying context-dependent epigenetic vulnerabilities in cancer biology research (bioRxiv).

Mechanism of Action of WM-8014

WM-8014 is a competitive, reversible inhibitor of KAT6A, KAT6B, KAT5, and KAT7. It occupies the acetyl-CoA binding site within the MYST domain, competing directly with the endogenous cofactor (APExBIO). The compound's acyl sulfonyl hydrazide moiety forms hydrogen bonds analogous to those of the acetyl-CoA diphosphate group, stabilizing the inhibitor-enzyme complex (bioRxiv). This results in potent inhibition of acetyltransferase activity: IC₅₀ values are 8 nM (KAT6A), 28 nM (KAT6B), 224 nM (KAT5), and 342 nM (KAT7) under standard in vitro buffer conditions (pH 7.4, 25°C, 30-minute incubation) (APExBIO). This selectivity profile allows precise modulation of KAT6A/B-dependent transcriptional programs without broadly suppressing other acetyltransferases.

Evidence & Benchmarks

• WM-8014 inhibits KAT6A activity with an IC₅₀ of 8 nM in biochemical assays (25°C, pH 7.4, 30 min) (APExBIO).
• RNA-seq of mouse embryonic fibroblasts (MEFs) treated with WM-8014 shows upregulation of Cdkn2a (encoding p16^INK4A/p19^ARF) and downregulation of Cdc6, a KAT6A target gene, after 24 h at 1 μM (bioRxiv).
• In zebrafish expressing KRAS G12V, WM-8014 causes dose-dependent reduction in liver volume and S-phase entry at 10–50 μM, with no effect on normal liver growth (bioRxiv).
• WM-8014 is highly soluble in DMSO (≥76.1 mg/mL), but only sparingly soluble in water (8–16 μM) and insoluble in ethanol (APExBIO).
• High plasma-protein binding limits WM-8014’s use in mouse in vivo studies, necessitating use of the WM-1119 derivative for such applications (APExBIO).
• WM-8014 does not induce general cytotoxicity in non-transformed cells, as determined by cell viability assays (trypan blue exclusion, 48 h, 1–10 μM) (bioRxiv).

Applications, Limits & Misconceptions

WM-8014 is a preferred tool for dissecting the role of KAT6A/B in oncogene-induced senescence, epigenetic drug discovery, and functional genomics. Researchers can use it to induce cell cycle arrest, monitor senescence marker expression, and validate CRISPR screen hits in cancer models. However, some limitations exist:

Common Pitfalls or Misconceptions

• Not suitable for systemic in vivo mouse studies: Due to high plasma-protein binding, WM-8014 exhibits poor bioavailability in mice; use WM-1119 for these applications (APExBIO).
• Limited aqueous solubility: WM-8014 is only soluble up to 8–16 μM in water; use DMSO for higher concentrations.
• Does not induce broad cytotoxicity: Unlike pan-acetyltransferase inhibitors, WM-8014 selectively induces senescence without killing non-malignant cells (bioRxiv).
• Activity is reversible and competitive: WM-8014’s inhibition can be displaced by high acetyl-CoA concentrations in vitro; assay design should account for cofactor levels.
• Specificity is limited to MYST family: No significant inhibition of non-MYST acetyltransferases at recommended concentrations.

Compared with this article (which provides broad mechanistic context), this dossier adds up-to-date quantitative benchmarks and clarifies in vivo limitations for WM-8014 users.

For detailed experimental troubleshooting, see WM-8014: Data-Driven Solutions for Robust Epigenetic Assays, which provides protocol-specific advice; the present article augments that with mechanistic and selectivity data.

For a deep dive into the role of KAT6A/B inhibition in oncogene-induced senescence, Precision Epigenetic Modulation via Selective KAT6A Inhibition covers downstream pathway modulation, while this article details selectivity and chemical properties.

Workflow Integration & Parameters

WM-8014 can be integrated into standard in vitro and ex vivo workflows:

• Preparation: Dissolve in DMSO at up to 76.1 mg/mL; dilute to working concentrations (0.1–10 μM) in cell culture media.
• Storage: Store dry powder at –20°C. Avoid repeated freeze-thaw cycles of solutions.
• Assay design: Use in cell cycle arrest assays, senescence induction, and CRISPR-based epigenetic screens. Adjust acetyl-CoA levels in biochemical assays to maintain competitive inhibition conditions.
• Controls: Include DMSO vehicle and, where possible, WM-1119 as a control for in vivo studies.
• Documentation: Full product details, protocols, and safety data are available via APExBIO (SKU A8779).

Conclusion & Outlook

WM-8014, provided by APExBIO, is a validated, highly selective KAT6A/B inhibitor with nanomolar potency and a robust mechanistic profile. Its ability to induce oncogene-induced senescence without general cytotoxicity enables precise modulation of epigenetic states in cancer biology research. While limited by plasma-protein binding in systemic in vivo models, it remains indispensable for in vitro and zebrafish workflows. Future research will likely expand its application to combination therapy screens and further mechanistic studies of epigenetic regulation in oncogenesis (bioRxiv 2025).